Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 1/20 | 0.51 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.51 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.46 |
| ▸ | AMD1 | P17707 | 2/20 | 0.44 |
| ▸ | EPRS1 | P07814 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26611817 | 0.90 | RXFP1 (0.58) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30239020 | 0.82 | RXFP1 (0.44) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18314784 | 0.81 | PI4KA (0.58) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL30238896 | 0.81 | DOT1L (0.43) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31001597 | 0.81 | P2RX3 (0.51) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23121048 | 0.80 | PI4KA (0.55) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18314786 | 0.79 | PI4KA (0.55) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31001613 | 0.79 | P2RX3 (0.48) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23121063 | 0.79 | PI4KA (0.57) | RXFP1PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL23260482 | 0.78 | PI4KA (0.51) | RXFP1PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION | 2025-03-20 | — | — | US | disclosed |
| EP-4374157-A2 | FRET-BASED ASSAYS | The General Hospital Corporation (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023004438-A2 | FRET-BASED ASSAYS | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250093263-A1 | FRET-BASED ASSAYS | TARBP1, GTPBP4, TERF2IP | RXFP1 2124/4885PI4KA 2154/4885PI4K2B 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.